With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

CVS’ pharmacy benefit manager Caremark also reached an agreement with Danish drugmaker Novo Nordisk to give its weight loss drug Wegovy preferred access on Caremark’s standard formulary ...

So that's something good to look forward to. But going back to this CVS Novo Nordisk deal, that is, of course, the talk of the day. If you've seen Lily stock, it has taken a beating because of its ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

CVS Caremark to list Wegovy as preferred GLP-1 drug on top formularies starting July 1, 2025. Novo Nordisk plans continued collaboration with CVS to widen Wegovy access. Get 5 ‘Hidden Gem ...

Independent of this formulary decision, Novo Nordisk will continue to work with CVS to identify additional ways to expand access to Wegovy ® for its customers.

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

This will enable CVS Pharmacy to provide eligible patients at its 9,000 community health locations with convenient, safe, and affordable access to Novo Nordisk A/S' NVO Wegovy. Guidance ...